Trial Profile
Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2022
Price :
$35
*
At a glance
- Drugs Metformin (Primary) ; Rosiglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms STOPP-T2D; TODAY
- 03 Oct 2022 Results examining the effect of different patterns of durable glycemic control on the development of comorbidities in youth with type 2 diabetes and impact of fasting glucose variability on the clinical course of T2D, published in the Diabetes Care
- 07 Jun 2022 Results assessing impact of pregnancy on microvascular and cardiac outcomes, presented at the 82nd Annual Scientific Sessions of the American Diabetes Association.
- 29 Oct 2021 Results (n=674)assessing relationship of glycemic control, sex, race/ethnicity, BMI, and other type 2 diabetes-associated factors with the development of diabetic peripheral neuropathy (DPN) in youth with type 2 diabetes enrolled in the Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) studypublished in the Diabetes Care